Because the current human genome reference used by the global biomedical research community was predominantly derived from a Caucasian individual, its utility is limited for researchers investigating certain complex diseases that differ genetically between ethnicities. Macrogen, among others, has characterized these differences, for example in the publication of “A highly annotated whole-genome sequence of a Korean individual” in the journal Nature. These publications highlight the limitations of resequencing in building reference genomes that more accurately represent individual and ethnic differences. Macrogen will now use
SMRT Sequencing to generate high-quality ethnic genome references de novo.
In addition to the new human genome reference projects, Macrogen will use the two PacBio RS II DNA Sequencing Systems to carry out other important sequencing applications that cannot be done effectively with short-read sequencing technologies. These include full-length transcript sequencing, high-quality de novo assemblies of plant, animal and bacterial genomes, metagenome characterization, and targeting complex regions of the human genome such as the major histocompatibility region (including full-length sequencing of HLA genes).
“The PacBio technology has matured to a point where it is possible, and even advantageous, to use it for human genome applications because it is the only technology that can easily resolve complex regions and uncover genetic variations beyond single nucleotide polymorphisms,” said Professor
Macrogen, Inc. (www.macrogen.com), based in
and consumer genomics. With a global presence, Macrogen operates through U.S. subsidiaries in
About the PacBio RS II and SMRT Sequencing
Pacific Biosciences’ Single Molecule, Real-Time (SMRT) Sequencing technology achieves the industry’s longest read lengths, highest consensus accuracy and the least degree of bias. These characteristics, combined with the ability to detect many types of DNA base modifications (e.g., methylation) as part of the sequencing process, make the PacBio RS II an essential tool for many scientists studying genetic and genomic variation. The PacBio platform provides a sequencing solution that can address a growing number of complex medical, agricultural and industrial problems.
About Pacific Biosciences
Forward Looking Statements
This press release contains forward-looking statements regarding, among other things, the use of the Company’s products for sequencing human and other genomes and other future events. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control and that could materially affect actual results. Factors that could materially affect actual results can be found in the Company’s filings with the
CONTACT: For Pacific Biosciences: Media:
Nicole Litchfield415.793.6468 email@example.com Investors: Trevin Rard650.521.8450 firstname.lastname@example.org For Macrogen: Mr. Yonghwan Kang+82-2-2113-7113 email@example.com
News Provided by Acquire Media